Prescriptions for Spravato, which is psychedelic-based drug made by Johnson & Johnson, are booming and new clinics are opening that specialize in administering it, Peter Loftus of The Wall Street Journal reports. Sales are rising so much that Spravato is now a key part of the company’s lineup and analysts expect the drug to surpass $1B in annual sales this year. Spravatos’ upward trajectory demonstrates the challenges and opportunities for the use of the drugs in mental health. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.
Source: Wall Street Journal October 21, 2024 11:29 UTC